---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-078322"
form_type: "8-K"
ticker: "IPSC"
cik: "0001850119"
company_name: "Century Therapeutics, Inc."
filed_at: "2024-07-08T23:59:59+00:00"
generated_at: "2026-05-31T23:08:12.528345+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Century Therapeutics updates pipeline; CNTY-101 achieves 40% CRR at higher doses; SLE trial starts Q3 2024

## Summary
- CNTY-101 ELiPSE-1 Phase 1 data: 30% CRR, 40% ORR overall; 40% CRR, 60% ORR at highest dose levels in Schedule A.
- CNTY-101 shows favorable safety: no GvHD, low-grade CRS/ICANS, manageable outpatient administration.
- Phase 1 CALiPSO-1 trial for SLE (systemic lupus erythematosus) initiated early Q3 2024; initial data expected by YE 2024.
- Cash of $249.9M at 1Q24 end provides runway into 2026.
- Pursuing additional autoimmune regulatory submissions for CNTY-101 in 2H 2024.

## SEC filing metadata
- accession: 0001104659-24-078322
- form_type: 8-K
- ticker: IPSC
- cik: 0001850119
- company_name: Century Therapeutics, Inc.
- filed_at: 2024-07-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1850119/000110465924078322/0001104659-24-078322-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1850119/000110465924078322/tm2418927d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-078322
- JSON: https://secwatch.observer/filing/0001104659-24-078322.json
- Plain text: https://secwatch.observer/filing/0001104659-24-078322.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.